With the notable exception of DFS for HER2-positive early-stage breast cancer [13], composite endpoints have shown some correlation with OS at the individual level but have failed to demonstrate any consistent strong correlation between treatment effect on the candidate surrogate and treatment effect on OS at the trial level [14,15,16]. This evidence concerns the gene ERBB2 and breast cancer.